Matches in SemOpenAlex for { <https://semopenalex.org/work/W2336107788> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W2336107788 endingPage "v29" @default.
- W2336107788 startingPage "v29.2" @default.
- W2336107788 abstract "INTRODUCTION: The DNA alkylating agent, temozolomide (TMZ), given during and after radiotherapy (RT) improves the survival of patients with glioblastoma (GBM). TMZ is unequivocally helpful for patients with GBMs in which the DNA repair protein, O6-methylguanine-DNA methyltransferase (MGMT), has been silenced by methylation of the MGMT gene promoter (i.e., 40%). For the remainder, whose GBMs express MGMT, and are therefore more resistant to TMZ, the addition of TMZ to RT adds little benefit. Moreover, many who benefit initially acquire resistance to TMZ through treatment-induced mutations. The need for other therapies for GBM motivated us to re-examine carboplatin, a DNA crosslinking agent whose development for use against GBM was curtailed by the emergence of TMZ. Carboplatin is well tolerated and crosses the blood brain barrier, making it an agent of interest. METHODS: Ten brain tumor initiating cell (BTIC) lines derived from newly diagnosed or previously treated GBMs were assessed for sensitivity to carboplatin (5 or 10 ug/mL for 8 days) or TMZ (10 ug/mL for 8 days); viability was measured using the AlamarBlue assay. RESULTS: All BTICs were sensitive to carboplatin; lines derived from untreated methylated GBMs were equally sensitive to carboplatin and TMZ. Sensitivity to TMZ was only observed in BTICs that were MGMT methylated and derived from untreated patients. BTICs with an unmethylated MGMT promoter that were derived from newly diagnosed patients were resistant to TMZ, as where those from previously treated patients. CONCLUSIONS: TMZ resistance, is a major obstacle to the successful treatment of GBM; hence, the need for alternatives to TMZ. This study demonstrates that carboplatin is active against BTICs, and may be useful in situations where resistance to TMZ is seen. Although in vivo work is required to bolster the relevance of this finding, our observations suggest that carboplatin may be warrant further study for GBM." @default.
- W2336107788 created "2016-06-24" @default.
- W2336107788 creator A5000632665 @default.
- W2336107788 creator A5019512808 @default.
- W2336107788 creator A5020247797 @default.
- W2336107788 creator A5038812862 @default.
- W2336107788 date "2015-11-01" @default.
- W2336107788 modified "2023-09-25" @default.
- W2336107788 title "ATPS-50REVISITING CARBOPLATIN AS A THERAPY FOR GLIOBLASTOMA (GBM)" @default.
- W2336107788 doi "https://doi.org/10.1093/neuonc/nov204.50" @default.
- W2336107788 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4638473" @default.
- W2336107788 hasPublicationYear "2015" @default.
- W2336107788 type Work @default.
- W2336107788 sameAs 2336107788 @default.
- W2336107788 citedByCount "0" @default.
- W2336107788 crossrefType "journal-article" @default.
- W2336107788 hasAuthorship W2336107788A5000632665 @default.
- W2336107788 hasAuthorship W2336107788A5019512808 @default.
- W2336107788 hasAuthorship W2336107788A5020247797 @default.
- W2336107788 hasAuthorship W2336107788A5038812862 @default.
- W2336107788 hasBestOaLocation W23361077881 @default.
- W2336107788 hasConcept C126322002 @default.
- W2336107788 hasConcept C143998085 @default.
- W2336107788 hasConcept C2776194525 @default.
- W2336107788 hasConcept C2776694085 @default.
- W2336107788 hasConcept C2778239845 @default.
- W2336107788 hasConcept C2781451048 @default.
- W2336107788 hasConcept C502942594 @default.
- W2336107788 hasConcept C71924100 @default.
- W2336107788 hasConceptScore W2336107788C126322002 @default.
- W2336107788 hasConceptScore W2336107788C143998085 @default.
- W2336107788 hasConceptScore W2336107788C2776194525 @default.
- W2336107788 hasConceptScore W2336107788C2776694085 @default.
- W2336107788 hasConceptScore W2336107788C2778239845 @default.
- W2336107788 hasConceptScore W2336107788C2781451048 @default.
- W2336107788 hasConceptScore W2336107788C502942594 @default.
- W2336107788 hasConceptScore W2336107788C71924100 @default.
- W2336107788 hasIssue "suppl 5" @default.
- W2336107788 hasLocation W23361077881 @default.
- W2336107788 hasLocation W23361077882 @default.
- W2336107788 hasOpenAccess W2336107788 @default.
- W2336107788 hasPrimaryLocation W23361077881 @default.
- W2336107788 hasRelatedWork W1974753377 @default.
- W2336107788 hasRelatedWork W1977929023 @default.
- W2336107788 hasRelatedWork W2072767112 @default.
- W2336107788 hasRelatedWork W2130549011 @default.
- W2336107788 hasRelatedWork W2155095895 @default.
- W2336107788 hasRelatedWork W2350445292 @default.
- W2336107788 hasRelatedWork W3094218903 @default.
- W2336107788 hasRelatedWork W3204525731 @default.
- W2336107788 hasRelatedWork W4315752805 @default.
- W2336107788 hasRelatedWork W4214789906 @default.
- W2336107788 hasVolume "17" @default.
- W2336107788 isParatext "false" @default.
- W2336107788 isRetracted "false" @default.
- W2336107788 magId "2336107788" @default.
- W2336107788 workType "article" @default.